SOHO State of the Art Updates and Next Questions | Impact of Biologic Markers on Outcomes With Novel Therapy in Chronic Lymphocytic Leukaemia. [Review]
No Thumbnail Available
All Authors
Varghese, AM.
Munir, T.
LTHT Author
Varghese, Abraham
Munir, Talha
Munir, Talha
LTHT Department
Haematology
Non Medic
Publication Date
2025
Item Type
Journal Article
Review
Review
Language
Subject
Subject Headings
Abstract
Treatment of CLL has changed remarkably in the last decade and novel agents are the standard therapy in various jurisdictions. However, the biology of CLL still plays an important part in the treatment choice and disease outcomes. In this post chemo-immunotherapy era for CLL, number of biological factors have lost their clinical significance and most patients will benefit from continuous or time-limited therapy. However, TP53 and IGHV mutation status still retains clinical significance in determining outcomes with various therapeutic approaches. New emerging biological markers including drug-specific mutations are adding to the complexity of decision making in relapsed CLL. End of treatment minimal residual disease analysis (MRD) adds prognostic information to the outcomes with time-limited therapy. MRD-guided duration of treatment may improve further outcomes, but longer clinical follow-up is needed before this approach is incorporated in clinical guidelines. The review gives an update on the impact of biological markers on outcomes with novel agents. Crown
Journal
Clinical lymphoma, myeloma & leukemia